NYSE$JNJ
Johnson & Johnson · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Johnson & Johnson's second quarter performance reflected a focus on medical innovation, resulting in strong sales and adjusted operational earnings per share growth.
Johnson & Johnson reported a 4.3% increase in sales to $22.4 billion and an EPS of $1.93, which decreased by 5.9%. Adjusted EPS increased by 10.2% to $2.82. The company has increased its full-year 2024 operational sales guidance to reflect the acquisition of Shockwave Medical and updated its full-year 2024 adjusted operational EPS guidance to reflect improved performance.
- Second-Quarter sales increased by 4.3% to $22.4 Billion.
- Second-Quarter Earnings per share (EPS) decreased by 5.9% to $1.93.
- Adjusted EPS increased by 10.2% to $2.82.
- Full-Year 2024 operational sales guidance increased to reflect the acquisition of Shockwave Medical.
Headline financials
Revenue & EPS history
Johnson & Johnson · Revenue · Quarterly
$22.4B
Revenue by segment
Johnson & Johnson · $19.9B total across 2 segments · Q1 2023
- Innovative Medicine$13.2B+8.8%66.0%
- MedTech$6.78B+3.0%34.0%
Forward guidance
Johnson & Johnson is updating its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact for the recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.
Tailwinds
- Improved performance outlook
- Operational Sales between $89.2B – $89.6B
- Adjusted Operational EPS between $10.00 – $10.10
- Estimated Reported Sales between $88.0B – $88.4B
- Adjusted EPS between $9.97 – $10.07
Headwinds
- Costs associated with recent strategic acquisitions more than offset the improvement
- M&A impact of ($0.68) on Adjusted Operational EPS
- Acquisition of Shockwave Medical
- Acquisition of Proteologix
- Acquisition of NM26 Bispecific Antibody
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.8%
Avg return
30 days after
54%
37 / 69 earnings
Positive
+7.2%
Q2 2023
Best reaction
-4.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -1.6% | -3.8% | |
| Q4 2025 | -0.4% | +1.5% | +11.1% | |
| Q3 2025 | +0.1% | +1.2% | +2.3% | |
| Q2 2025 | +0.9% | +2.0% | +3.1% | |
| Q1 2025 | -0.5% | +2.0% | -3.1% | |
| Q4 2024 | -1.9% | +3.2% | +9.6% | |
| Q3 2024 | +1.7% | +2.2% | -6.0% | |
| Q2 2024 | +2.9% | +2.1% | +5.5% | |
| Q1 2024 | -1.9% | +0.2% | +4.5% | |
| Q4 2023 | -2.2% | -1.8% | -1.2% | |
| Q3 2023 | -3.0% | -2.9% | -4.7% | |
| Q2 2023 | +7.2% | +8.6% | +8.7% | |
| Q1 2023 | -1.9% | -1.8% | -4.3% | |
| Q4 2022 | +0.7% | -0.0% | -6.3% | |
| Q3 2022 | -1.1% | +1.3% | +5.0% | |
| Q2 2022 | -2.0% | -1.2% | -4.3% | |
| Q1 2022 | +3.5% | +2.2% | -2.1% | |
| Q4 2021 | +3.3% | +5.4% | -3.0% | |
| Q3 2021 | +2.3% | +2.2% | +1.4% | |
| Q2 2021 | +0.9% | +2.0% | +6.5% | |
| Q1 2021 | +2.4% | +1.7% | +5.2% | |
| Q4 2020 | +1.1% | -1.7% | -1.9% | |
| Q3 2020 | -2.5% | -2.5% | -2.3% | |
| Q2 2020 | +0.7% | +1.0% | -0.0% | |
| Q1 2020 | +5.6% | +8.8% | +5.6% | |
| Q4 2019 | -0.5% | -0.3% | +0.4% | |
| Q3 2019 | +3.4% | -2.3% | +0.2% | |
| Q2 2019 | -2.1% | -3.3% | -3.1% | |
| Q1 2019 | +1.5% | +0.7% | +1.2% | |
| Q4 2018 | -1.4% | -1.9% | +3.6% | |
| Q3 2018 | +4.1% | +3.8% | +7.9% | |
| Q2 2018 | +2.5% | +0.9% | +6.2% | |
| Q1 2018 | -3.1% | -3.9% | -6.0% | |
| Q4 2017 | -4.1% | -1.9% | -12.3% | |
| Q3 2017 | +3.3% | +4.6% | +2.0% | |
| Q2 2017 | +2.3% | +2.4% | +0.7% | |
| Q1 2017 | -3.5% | -3.1% | +1.0% | |
| Q4 2016 | -1.0% | -0.5% | +6.8% | |
| Q3 2016 | -3.3% | -4.3% | -1.6% | |
| Q2 2016 | +1.6% | +1.5% | -2.0% | |
| Q1 2016 | +2.4% | — | — | |
| Q4 2015 | +6.0% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.1% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | -2.1% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | -3.0% | — | — | |
| Q1 2014 | +1.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | +1.5% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | +2.7% | — | — | |
| Q4 2012 | -0.5% | — | — | |
| Q3 2012 | +3.5% | — | — | |
| Q2 2012 | +1.3% | — | — | |
| Q1 2012 | -1.1% | — | — | |
| Q4 2011 | +2.0% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | -1.5% | — | — | |
| Q1 2010 | +2.1% | — | — | |
| Q1 2011 | -0.6% | — | — | |
| Q4 2007 | +0.7% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2010 | +1.8% | — | — | |
| Q3 2008 | +1.8% | — | — | |
| Q4 2008 | -1.1% | — | — | |
| Q2 2008 | -1.1% | — | — | |
| Q2 2010 | -1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro